FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and can be used for treating acquired disorder resistant to methotrexate in a subject. For this purpose, said subject suffering from acquired disorder resistant to methotrexate is administered a pharmaceutically effective amount of a composition which contains 10-propargyl-10-deazaaminopterin or pharmaceutically acceptable salts thereof. Also provided is a method of treating a subject in need of treatment for acquired neoplasia.
EFFECT: group of inventions provides effective treatment of acquired disorders resistant to methotrexate in a subject, such as: neoplasia, rheumatoid arthritis.
12 cl, 20 dwg, 6 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF CONSTRUCTING ALLOGENIC AND DRUG RESISTANT T-CELLS FOR IMMUNOTHERAPY | 2014 |
|
RU2689558C1 |
| METHODS OF TREATING CDK4/6 INHIBITOR-RESISTANT CANCER | 2019 |
|
RU2820478C2 |
| METHODS FOR SELECTING EUKARYOTIC CELLS, EXPRESSING HETEROLOGOUS PROTEIN | 2010 |
|
RU2551229C2 |
| PROCESS FOR PREPARING FABRIC-TYPE PLASMINOGENE ACTIVATOR, STRAIN OF CULTIVATED ANIMAL CELLS, FABRIC-TYPE PLASMINOGENE ACTIVATOR CHO PRODUCER | 1987 |
|
RU2046827C1 |
| METHODS OF TREATING CANCER ON MODELS HAVING ESR1 MUTATIONS | 2019 |
|
RU2822195C2 |
| ANTI-PTK7 ANTIBODY-DRUG CONJUGATES | 2015 |
|
RU2708075C2 |
| DUOCARMICIN ADC SHOWING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2689779C2 |
| DUOCARMYCIN ADCs EXHIBITING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2769700C2 |
| METHODS OF TREATING AR+ BREAST CANCER | 2017 |
|
RU2769527C2 |
| METHODS BASED ON DETECTING RAD51 FOCI IN TUMOUR CELLS | 2018 |
|
RU2825699C2 |
